Tay Salimullah

Vice President, Global Head Value & Access Novartis Gene Therapies

As Vice President, Global Head of Value & Access, Tay is currently building a 21st century integrated access function to transform rare diseases through gene therapies. Overseeing translational access; gene pricing & contracting, geneconomics; real-world data; and public policy. He has diverse global market access, pricing, and commercial experience across biopharmaceuticals, consultancy, social sector and private equity. Since joining Novartis in 2013, Tay has led strategic and operations teams across various divisions in Pharma, Region Europe, Oncology, Cell & Gene Therapies (part of the original team that lead the first FDA approved cell therapy Kymriah® for children with acute lymphoblastic leukemia) and Group Global Health (launching the enterprise flagship sickle cell disease program).

He was a founding member of Harmony®, the largest real-world data program in hematology in Europe. He is focused on inspiring associates to think early and differently about patient access and reimbursement. Before Novartis Tay spent 11 years with Pfizer, where he held positions of increasing responsibility within commercial, market access and strategy development. In 2009, Tay completed his Global Health Fellowship: in-field health care systems experience in Malawi. He has also worked for a private investment group to incubate healthcare access across Asia. He has lived and worked in Europe, Asia, Africa and the USA and passionate about breakthrough thinking to transform global patient access.

Our website uses cookies, including third parties’ profiling cookies, to improve the functionality of the site and your user experience. You can learn more about how we use cookies and how to change your cookies settings in our Privacy Policy. By closing this message, clicking below or continuing to use this site, you consent to our use of cookies.